Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

18 Oct 2010

African-American children have higher risk of hypertension

Persistently high blood pressure, or hypertension, may spell worse heart trouble for black children under the age of 13 than for other children of the same ages, according to research led by scientists at Johns Hopkins Children's Center and published in the November issue of Pediatrics.

18 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

FDA plans to revoke knee implant approval following intense political pressure for its approval

The Food and Drug Administration on Thursday said it planned to revoke a medical-device company's right to sell a knee implant called Menaflex after an unprecedented yearlong review concluded the agency erred in allowing it on the market

18 Oct 2010

Scientists find unexpected function of cell's protein-making machinery

When cells make the proteins that carry out virtually every function of life, it's vital that the right things happen at the right times, and maybe more importantly that wrong things are stopped from happening at the wrong times.

18 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

Issuing first report on NTDS, WHO aims for 'complete control' by 2015

The WHO said on Thursday that it was aiming for 'complete control' by 2015 of tropical diseases that affect one billion impoverished people and kill an estimated 534,000 people each year, Agence France-Presse reports.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Prolong Pharmaceuticals receives $30 million from private investor group

Prolong Pharmaceuticals today announced that the company has received a commitment of $30 million in funding from a private investor group. The monies will be dedicated to the company's continuing research and development efforts and clinical programs targeting anemias resulting from oxygen deficiency.

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Risingsun signs consent decree to stop selling unapproved drugs

The U.S. Food and Drug Administration today announced that Toby McAdam and Greta Armstrong, doing business as Risingsun Health and The Center for Complimentary and Alternative Health of Livingston, Montana, have signed a consent decree that prohibits them from manufacturing and selling unapproved new drugs and adulterated or misbranded dietary supplements in violation of the law.

14 Oct 2010

GSK to expand donation of albendazole medicine to treat children with STH risk

At the launch of the World Health Organization's (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its medicine albendazole to treat children at risk of intestinal worms, known as soil-transmitted helminths (STH).

14 Oct 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.

14 Oct 2010

Studies examine risk factors for hospital readmission

In two studies published today in the Journal of Hospital Medicine, the risk factors for readmission to the hospital are examined based upon general medicine inpatients and those with at least two admissions in a six-month period. Alongside clinical factors such as having cancer, chronic diseases such as heart failure or lung disease, or being on high-risk medications, the studies identified other factors which increase the likelihood of a patient being readmitted which could help hospitalists focus in on these groups.

13 Oct 2010

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

Use of stricter guidelines for the use of red blood cell transfusions for patients undergoing cardiac surgery was associated similar rates of death and severe illness compared to patients who received more transfusions, according to a study in the October 13 issue of JAMA. Another study in this issue of JAMA examines the variation in the use of blood transfusions for patients undergoing cardiac surgery.

13 Oct 2010

NBM 200 system accurately measures hemoglobin level

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented today at the AABB Annual Meeting & CTTXPO 2010, in Baltimore, Maryland, results showing that hemoglobin (Hb) measurements obtained by its NBM 200, a non-invasive Hb measurement system for anemia screening, showed accurate performance compared with invasive point of care (POC) devices.

11 Oct 2010

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.

11 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Cincinnati Children's Hospital Medical Center has been named one of five national Centers of Excellence for Molecular Hematology to find new gene and cell therapies for inherited diseases affecting blood cells.

8 Oct 2010

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

7 Oct 2010

Anemia News and Research

Further Reading

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

African-American children have higher risk of hypertension

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

FDA plans to revoke knee implant approval following intense political pressure for its approval

Scientists find unexpected function of cell's protein-making machinery

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Issuing first report on NTDS, WHO aims for 'complete control' by 2015

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

Prolong Pharmaceuticals receives $30 million from private investor group

FDA approves Gamunex-C for primary immunodeficiency treatment

Risingsun signs consent decree to stop selling unapproved drugs

GSK to expand donation of albendazole medicine to treat children with STH risk

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Studies examine risk factors for hospital readmission

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

NBM 200 system accurately measures hemoglobin level

Allos announces favorable survival data from FOLOTYN Phase 2b study

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News